Patients bearing tumours expressing high NCL mRNA levels, but also unexpectedly the ones expressing low NCL mRNA levels, had poorer overall and disease-free survivals than other breast cancer patients even when adjusted to two robust clinical factors, tumour size and lymph node invasion status. The gene discussed is NUCLEOLIN; the disease is breast cancer.